afamelanotide   Click here for help

GtoPdb Ligand ID: 1324

Synonyms: α-NDP-MSH | [Nle4,dPhe7]α-MSH | CUV-1647 | CUV1647 | NDP-MSH | Scenesse®
Approved drug
afamelanotide is an approved drug (EMA (2014), FDA (2019))
Comment: Afamelanotide is a synthetic analogue of α-MSH, and is a first-in-class clinically used non-selective MC receptor agonist. It is used for certain dematological applications [5-6].
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N1CCCC1C(=O)NC(C(=O)N)C(C)C)CCCCN)Cc1c[nH]c2c1cccc2)CCCNC(=N)N)Cc1ccccc1)Cc1[nH]cnc1)CCC(=O)O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C)CO)Cc1ccc(cc1)O)CO
Isomeric SMILES CCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)C(C)C)CCCCN)Cc1c[nH]c2c1cccc2)CCCNC(=N)N)Cc1ccccc1)Cc1[nH]cnc1)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CO)Cc1ccc(cc1)O)CO
InChI InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1
InChI Key UAHFGYDRQSXQEB-LEBBXHLNSA-N
No information available.
Summary of Clinical Use Click here for help
Afamelanotide is approved to prevent phototoxicity in adults with erythropoietic protoporphyria [2-3,5].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Afamelanotide stimulates the production of eumelanin in the skin to provide protection against the phototoxic effects of exposure to sunlight in patients with erythropoietic protoporphyria.
External links Click here for help